Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement

被引:15
|
作者
Mariathasan, A. B. [1 ,2 ]
Boye, K. [3 ,4 ]
Giercksky, K. E. [1 ,2 ]
Brennhovd, B. [5 ]
Gullestad, H. P. [6 ]
Emblemsvag, H. L. [7 ]
Groholt, K. K. [8 ]
Dueland, S. [3 ]
Flatmark, K. [1 ,2 ,4 ]
Larsen, S. G. [1 ]
机构
[1] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Gastroenterol Surg, Sect Surg Oncol, N-0310 Oslo, Norway
[2] Univ Oslo, Fac Med, Oslo, Norway
[3] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway
[4] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Tumour Biol, Oslo, Norway
[5] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Urol, Sect Surg Oncol, Oslo, Norway
[6] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Plast Surg, Sect Surg Oncol, Oslo, Norway
[7] Oslo Univ Hosp, Dept Radiol, Sect Oncol Radiol, Norwegian Radium Hosp, Oslo, Norway
[8] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway
来源
EJSO | 2018年 / 44卷 / 08期
关键词
Locally advanced rectal cancer; Beyond TME surgery; Multivisceral resection; Chemo-radiotherapy; Pelvic side-wall infiltration; MULTIVISCERAL RESECTIONS; INDUCTION CHEMOTHERAPY; PROGNOSTIC-FACTORS; COLORECTAL-CANCER; EXENTERATION; TUMOR; DETERMINANTS; CARCINOMA; SURVIVAL; SURGERY;
D O I
10.1016/j.ejso.2018.03.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In locally advanced rectal cancer (LARC), beyond total mesorectal excision (bTME) is often necessary to obtain complete resection (RO). The aim of this study was to identify prognostic determinants and compare morbidity and survival in LARC cases requiring bTME or TME surgery. Method: Single centre cohort study of LARC cases where all patients received neoadjuvant radiotherapy (n = 332). Data was registered prospectively in an institutional database linked to the National Registry. Results: bTME surgery was performed in 224 patients, 171 with resections of adjacent organs (bTME-o group) and 53 with pelvic side-wall resections (bTME-pw group). TME surgery was performed in 108 patients. Six deaths occurred within 100 days and severe morbidity was registered in 23.8% of the whole cohort and in 25.4% of the bTME groups. The RO rates were 93.5%, 84.2%, and 75.5% in the TME, bTME-o, and bTME-pw groups, respectively. Five-year disease free survival (DFS) was 67.3% (TME group), 54.5% (bTME-o group) and 48.7% (bTME-pw group), and five-year overall survival (OS) 78.7%, 69.0% and 60.4% respectively. Patients with involved resection margins (R1), high pT-stage, pN-positivity or poor response to neoadjuvant therapy were associated with inferior DFS and OS. Conclusion: In organ-threatening or infiltrating LARC, bTME surgery can be performed with low mortality and acceptable morbidity to obtain a good long-term outcome. Patients with pelvic side-wall infiltration were identified as a subgroup with increased risk of R1 resection and inferior long-term outcome. 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:1226 / 1232
页数:7
相关论文
共 50 条
  • [21] Survival after surgery beyond total mesorectal excision for primary locally advanced rectal cancer, a population-based study
    Bolmstrand, Bjorn
    Nilsson, Per J.
    Eloranta, Sandra
    Martling, Anna
    Buchli, Christian
    Palmer, Gabriella
    EJSO, 2024, 50 (12):
  • [22] Predictors of short-term readmission after beyond total mesorectal excision for primary locally advanced and recurrent rectal cancer
    Liccardo, Filomena
    Baird, Daniel L. H.
    Pellino, Gianluca
    Rasheed, Shahnawaz
    Kontovounisios, Christos
    Tekkis, Paris P.
    UPDATES IN SURGERY, 2019, 71 (03) : 477 - 484
  • [23] Predictors of short-term readmission after beyond total mesorectal excision for primary locally advanced and recurrent rectal cancer
    Filomena Liccardo
    Daniel L. H. Baird
    Gianluca Pellino
    Shahnawaz Rasheed
    Christos Kontovounisios
    Paris P. Tekkis
    Updates in Surgery, 2019, 71 : 477 - 484
  • [24] From Total Mesorectal Excision to Organ Preservation for the Treatment of Rectal Cancer
    Baek, Seong Kyu
    ANNALS OF COLOPROCTOLOGY, 2019, 35 (02) : 51 - 52
  • [25] Laparoscopic Total Mesorectal Excision with Enbloc Resection of Seminal Vesicle for Locally Advanced Rectal Adenocarcinoma
    Pai, Vishwas D.
    Bhandare, Manish
    Saklani, Avanish P.
    JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES, 2016, 26 (03): : 209 - 212
  • [26] Laparoscopic Total Mesorectal Excision With Coloanal Anastomosis for Rectal Cancer
    Denost, Quentin
    Adam, Jean-Philippe
    Pontallier, Arnaud
    Celerier, Bertrand
    Laurent, Christophe
    Rullier, Eric
    ANNALS OF SURGERY, 2015, 261 (01) : 138 - 143
  • [27] Long-term outcomes after laparoscopic total mesorectal excision for advanced rectal cancer
    Liu, L.
    Cao, Y.
    Zhang, G.
    Zhang, L.
    Wang, P.
    Gong, J.
    SOUTH AFRICAN JOURNAL OF SURGERY, 2011, 49 (04) : 186 - 189
  • [28] Prognostic Value of Lymph Node Ratio in Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy Followed by Total Mesorectal Excision
    Zuo, Zhi-Gui
    Zhang, Xiu-Feng
    Wang, Hao
    Liu, Qi-Zhi
    Ye, Xing-Zhao
    Xu, Chang
    Wu, Xiang-Bin
    Cai, Jian-Hui
    Zhou, Zhen-Hua
    Li, Jin-Lei
    Song, Hua-Yu
    Luo, Zu-Qiang
    Li, Peng
    Ni, Shi-Chang
    Jiang, Lei
    MEDICINE, 2016, 95 (09)
  • [29] Timing of additional neoadjuvant chemotherapy in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and total mesorectal excision
    Fang He
    Mo Chen
    Yan-ping Liu
    Jiachun Sun
    Jian Zheng
    Discover Oncology, 13
  • [30] Predicting Difficult Laparoscopic Total Mesorectal Excision for Locally-advanced Mid-low Rectal Cancer: The EuMaRCS Score Validation
    de'Angelis, Nicola
    Martinez-Perez, Aleix
    Vitali, Giulio Cesare
    Pigneur, Frederic
    Luciani, Alain
    Brunetti, Francesco
    Kraft, Miquel
    Marti-Martinez, Eva
    Moroni, Paolo
    Espin, Eloy
    Ris, Frederic
    Pucciarelli, Salvatore
    ANTICANCER RESEARCH, 2020, 40 (04) : 2079 - 2087